PRE-PROGRAMA
VIERNES 19 DE FEBRERO
15:30-15:40 Bienvenida
15:40-16:00 Presentación de abstracts sobre sitagliptina 2015
Dr. Esteban Jódar Gimeno
16:00-16:15 Conferencia introductoria
xxxxxxxxx
Dra. Rebeca Reyes
16:15-17:45 Módulo 1. Sesiones plenarias
Moderador: Dr. Manuel Muñoz Torres
Dr. Alberto Moreno Carazo
[ADA Diabetes Care Symposium] Novel Clinical Interventions in Therapy That Impact the Management of Diabetes
Dr. Elías Delgado Álvarez
[EASD/ESC] Symposium Lesson leaarned from glucose lowering trials
Dr. Javier Escalada San Martín
[EASD] The liver in focus
Dra. Noemí González Pérez de Villar
[ADA] Cardiovascular disease risk factor management in type 2 diabetes mellitus. Where are we in 2015?
Dra. Sharona Azriel Mira
[ADA] SGLT2 Blockers in 2015
17:45-18:15 Café
18:15-19:45 Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo
Moderador: Dr. José M.a Hernández i Anguera
Dr. Alberto Moreno Carazo
[ADA 65-OR] The Role of Glycemia in Insulin Resistance in Youth with Type 1 and Type 2 Diabetes
[ADA 75-OR] Early Metabolomic Profi ling Scores Improves the Prediction of Type 2 Diabetes in the Prospective D.E.S.I.R. Study
Dr. Elías Delgado Álvarez
[EASD 49] Consecuencias económicas de la inercia terapéutica en UK
[EASD 17] Riesgo de ca de páncreas y tratamientos antidiabéticos en la cohorte danesa
Dr. Javier Escalada San Martín
[EASD 10] Glycaemic control and incidence of dementia in 363,573 patients with type 2 diabetes: an observational study
[EASD 120] Epigenetic effects of maternal type 1 diabetes: placental dna methylations, mirnas and their effect on gene expression |
Dra. Noemí González Pérez de Villar
[ECE] Nocturnal blood pressure cut off points related to the development of microvascular complications and arterial hypertension in patients with type 1 diabetes
[ECE] Insulin-induced lipohypertrophy diagnostics in diabetic patients: subcutaneous fat ultrasonography
Dra. Sharona Azriel Mira
[ADA 124-lb] Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.
[ADA 55-OR] Surveillance of Cardiovascular Events and Total Mortality among Insured Adults With and Without Diabetes: The SUPREME Cohort Study
21:30 Cena
SÁBADO 20 DE FEBRERO
09:30-11:00 Módulo 3. Clínica y tratamiento (I)
Moderador: Dr. Pedro Mezquita Raya
Dr. Alberto Moreno Carazo
[ADA 77-OR] Incidence of Diabetes among Spouses of People with Diabetes
[ADA 93-OR] Basal Insulin Peglispro (BIL) Is Superior to Insulin Glargine (GL) in Reducing HbA1c at 52 Wks in Insulin-Naïve T2D Patients (Pts) Treated with Oral Antihyperglycemic Medications (OAMs): IMAGINE 2
Dr. Elías Delgado Álvarez
[EASD 53] Estudio de coste-eficacia entre mdi vs csii en dm 2 en Holanda
[EASD 153] Eficacia de los distintos tipos de intensificación tras el fallo de la insulina basal
Dr. Javier Escalada San Martín
[EASD 16] Differential effects of glp-1 receptor agonists on 24-hour averaged heart rate in healthy volunteers and patients with type 2 diabetes
[EASD 110] Omarigliptin, a once-weekly dpp-4 inhibitor, provides similar glycaemic control to sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on metformin
Dra. Noemí González Pérez de Villar
[ADA 72-OR] Once-weekly combination of glp-1r agonist and insulin (hm14220) offers improved glycemic control and reduced weight gain risk Jung kuk kim
[ECE] Novel glucagon receptor antagonist peptides improve glycaemic control and partially protect against streptozotocin induced diabetes in mice Finbarr o’harte
Dra. Sharona Azriel Mira
[ADA 76-OR] Clinical impact of itca 650 in type 2 diabetes: a randomized, double-blind, placebo-controlled, 39-week.
[ADA 96-OR] Unique profile of the weekly insulin hm12470: very slow onset of action, rapid off-rate similar to insulin, and absence of insulin receptor down regulation
11:00-11:30 Café
11:30-13:00 Módulo 4. Clínica y tratamiento (II)
Moderador: Dr. Francisco Tinahones Madueño
Dr. Alberto Moreno Carazo
[ADA 105-OR] A Randomized, Double-Blind, Phase 3 Trial of Dapaglifl ozin Add-on to Saxagliptin + Metformin in Type 2 Diabetes
[ADA 123-OR] Intestinal Preproglucagon Is Not Necessary for the Glucoregulatory Effects of DPP-4 Inhibitors
Dr. Elías Delgado Álvarez
[EASD 185] Dapa reduce albuminuria en DM2
Actualización de cetoacidosis con isglt-2
Dr. Javier Escalada San Martín
[EASD 122] Reactive hypoglycaemia after roux-en-y gastric bypass in type 2 diabetic subjects
[EASD 158] Efficacy and safety of alirocumab in individuals with diabetes: analyses from the odyssey long term study
Dra. Noemí González Pérez de Villar
[ADA 277-OR] Efficacy and Safety of Liraglutide Added to Insulin in Type 1 Diabetes: The LIRA-1 Trial
[ECE] Maintenance of risk reduction during 3-year follow up in prevention of type 2 diabetes by lifestyle intervention in primary health care setting: diabetes in europe prevention using lifestyle, physical activity and nutritional intervention (de-plan) project
Dra. Sharona Azriel Mira
[ADA] The evaluation of lixisenatide in acute coronary síndrome- the results of elixa.
[ADA 166-OR] Insulin degludec/liraglutide (ideglira) is superior to insulin glargine (ig) in a1c reduction, risk of hypoglycemia, and weight change: dual
13:00-13:15 Conferencia de cierre (¿Qué esperamos del 2016?)
Dr. Manel Puig Domingo
13:15 Cierre de la sesión
